Could a pill replace chemo for advanced breast cancer? new trial aims to find out.

NCT ID NCT07615751

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial compares an all-oral drug combination (pyrotinib, trastuzumab, and dalpiciclib) against standard chemotherapy plus targeted drugs for advanced HER2-positive breast cancer. About 502 patients who have had at most one prior treatment will be enrolled. The goal is to see if the oral regimen works as well as chemo but with fewer side effects and greater convenience.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pyrotinib, trastuzumab, dalpiciclib
What this could lead to: If successful, this could offer a more convenient and less toxic oral treatment option for advanced HER2-positive breast cancer, potentially replacing chemotherapy.
What could go wrong: This is a non-inferiority trial, so the oral combo may prove no better than chemo and could still fail to control the disease. Side effects from the new drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HER2-POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Fudan Cancer Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200230, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.